Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics

The advent of immunotherapy is a game changer in cancer therapy with monoclonal antibody- and T cell-based therapeutics being the current flagships. Small molecule immunotherapeutics might offer advantages over the biological drugs in terms of complexity, tissue penetration, manufacturing cost, stab...

Full description

Saved in:
Bibliographic Details
Published inActa pharmacologica Sinica Vol. 41; no. 7; pp. 881 - 894
Main Authors Van Herck, Simon, De Geest, Bruno G.
Format Journal Article
LanguageEnglish
Published Singapore Springer Singapore 01.07.2020
Nature Publishing Group
Subjects
Antibodies, Monoclonal - chemistry
Antibodies, Monoclonal - pharmacokinetics
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacokinetics
Biomedical and Life Sciences
Biomedicine
Humans
Immunology
Immunosuppressive agents
Immunotherapy
Internal Medicine
Lymphocytes T
Medical Microbiology
Monoclonal antibodies
Nanomedicine
Nanotechnology
Neoplasms - immunology
Neoplasms - therapy
Pharmacokinetics
Pharmacology/Toxicology
Review
Review Article
Shelf life
Small Molecule Libraries - chemistry
Small Molecule Libraries - pharmacokinetics
Toll-like receptors
Vaccine
stimulator of interferon genes (STING)
nanomedicine
pharmacokinetic profile
toll-like receptors
small molecule drugs
cancer immunotherapy
Online AccessGet full text

Cover

More Information
Summary:The advent of immunotherapy is a game changer in cancer therapy with monoclonal antibody- and T cell-based therapeutics being the current flagships. Small molecule immunotherapeutics might offer advantages over the biological drugs in terms of complexity, tissue penetration, manufacturing cost, stability, and shelf life. However, small molecule drugs are prone to rapid systemic distribution, which might induce severe off-target side effects. Nanotechnology could aid in the formulation of the drug molecules to improve their delivery to specific immune cell subsets. In this review we summarize the current efforts in changing the pharmacokinetic profile of small molecule immunotherapeutics with a strong focus on Toll-like receptor agonists. In addition, we give our vision on limitations and future pathways in the route of nanomedicine to the clinical practice.
ISSN:1671-4083
1745-7254
DOI:10.1038/s41401-020-0425-3